"Improving the well-being of people by allowing the monitoring of relevant parameters of blood out of the lab"





Bipolar disorder (BD) is a lifelong condition characterized by recurrent episodes of mania and depression, cognitive dysfunction and an increased risk of suicide. Lithium, Is the gold standard as mood stabilizer. It has a narrow therapeutic window, being effective in a small range of concentrations close to the toxic threshold. Lithium blood levels are monitored through inefficient, centralized, costly and time-consuming analysis leading to several problems such as intoxication. There is need for accessible, simple and affordable lithium level monitoring.

■ 70k€ Caixaimpulse

Biomed

■ 125k€ Sabadell Bstartup - Genesis

■ 160k€ Fundación Renal Iñigo Álvarez

■ 750k€ EIT Health Innovation by Ideas

■ 50k€ SME Instrument Phase I

■ 25k€ EIT-Health (PoC+)

(8 Partners Consortium)

■ 50% Clinical Validation

15% Technical Settings

15% Market Launch

MANAGING TEAM

20% Prototyping

globally

184M people affected

THE SOLUTION

BDSens is a paper-based ion-selective potentiometric

cell, strategically commercialized alongside a platform to connect physicians and patients at home, hospital or

The core technology lays on the ion-selective potentiometric

sensor, assembled in paper and composed by an ink and

The platform will support different sensor arrays, such as

6th leading cause of disability worldwide

**FUNDS RAISED** 

Raised

.18M€

Raising

2M€

**FUNDING GOALS** 



25-50% people with BD attempt suicide

interaction

2.330 M€ / year BD costs (Spain)







User-friendly with wireless connectivity and user centered design



Simple and minimally invasive Ultra - Low cost solution

**KEYMETRICS** 

±3€ Price / test

Revenue in 2021



Connected health fluid doctor to patient

350M€ /year Potential Market

2% Potential penetration rate

800 k€ Projected Gross Annual

MILESTONES

primary care.

2017 Foundation

2019 Functional Prototype

polymeric membranes.

creatinine and potassium.

2019 – 2020 Preclinical validation

2020 Final prototype

2020 Patent Application

2020 - 2021 Clinical validation

2021 CE Mark



Adrià Maceira CEO in





**Dr. Pascal Blondeau** cooin





Dr. Tomàs Guinovart CMO in

WITH THE SUPPORT OF



Agència de Qualitat i Avaluació Sanitàries de Catalunya



ACCELERATION PROGRAMS









Dra. Marta Novell СТО in



**Dr. Francisco Andrade** CINO in